INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE;UNIVERSITE CLAUDE BERNARD LYON 1;NETRIS PHARMA;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE;CENTRE LEON BERARD
发明人:
DUCAROUGE, BENJAMIN,GOLDSCHNEIDER, DAVID,REDAVID, ANNA MARIA RITA,GIBERT, BENJAMIN,MEHLEN, PATRICK
申请号：
CA3048347
公开号：
CA3048347A1
申请日:
2018.01.05
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
The invention is the combination or combined use of (i) a compound able to disrupt or impede netrin-1 /netrin-1 receptors interaction or netrin-1 -mediated receptor dimerization, also called herein a NTN1 neutralizing agent, which compound may be an antibody binding to netrin-1 or anti-netrin-1 antibody, and (ii) an immune checkpoint inhibitor, in the treatment of cancer. The composition may comprise an anti-netrin-1 antibody and an immune checkpoint inhibitor, for use as an anticancerous drug with a simultaneous, separate or sequential administration of the anti-netrin-1 antibody and the immune checkpoint inhibitor to a patient.
